{"id":7367,"date":"2010-05-05T04:46:09","date_gmt":"2010-05-05T08:46:09","guid":{"rendered":"http:\/\/asweetlife.org\/?p=7367"},"modified":"2015-12-29T07:15:30","modified_gmt":"2015-12-29T12:15:30","slug":"osiris-therapeutics-receives-fda-orphan-drug-designation-for-stem-cell-treatment-for-type-1-diabetes","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=7367","title":{"rendered":"Stem Cell Treatment for Type 1 Diabetes Receives FDA Orphan Drug Designation"},"content":{"rendered":"<p><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/05\/osiris-therapeutics-logo2.jpg\" rel=\"mfp\"><img decoding=\"async\" class=\"alignleft size-full wp-image-7375 lazyload\" style=\"margin: 4px;\" title=\"osiris-therapeutics-logo\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/05\/osiris-therapeutics-logo2.jpg\" alt=\"\" width=\"170\" height=\"69\" \/><\/a>Osiris Therapeutics, Inc. announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.<\/p>\n<p>Orphan Drug designation provides market exclusivity for up to seven years following approval, eliminates FDA filing and registration fees, and provides tax incentives for as much as 50 percent of the clinical development costs.<\/p>\n<p>Prochymal, a formulation of adult mesenchymal stem cells (MSC) designed to provide therapeutic benefit by controlling inflammation, promoting tissue regeneration, and preventing scar formation, is currently being evaluated in a double-blind, placebo-controlled Phase II clinical trial for type 1 diabetes. Osiris is developing Prochymal in partnership with the Juvenile Diabetes Research Foundation (JDRF) as a treatment for patients with newly diagnosed type 1 diabetes mellitus.<\/p>\n<p>In type 1 diabetes, the patient&#8217;s own immune system attacks and destroys insulin-producing islet cells in the pancreas, resulting in the loss of blood-sugar control. Currently, there are no approved treatments for altering the rate of destruction of these critical islet cells, called beta cells. Preclinical studies first conducted by researchers at Genzyme found that MSCs may delay the progression of type 1 diabetes by preserving beta cell function.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Osiris Therapeutics, Inc. announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations&#8230;<\/p>\n","protected":false},"author":131,"featured_media":7375,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1445],"tags":[1499],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Type 1 Diabetes Stem Cell Treatment Receives FDA Orphan Drug Designation<\/title>\n<meta name=\"description\" content=\"FDA grants Osiris Orphan Drug Designation for Type 1 Diabetes Stem Cell Treatment. Prochymal, a formulation stem cells (MSC) is being evaluated in Phase II clinical trial. Osiris is developing Prochymal in JDRF as a treatment for type 1 diabetes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=7367\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=7367\",\"url\":\"https:\/\/asweetlife.org\/?p=7367\",\"name\":\"Type 1 Diabetes Stem Cell Treatment Receives FDA Orphan Drug Designation\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=7367#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=7367#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/05\/osiris-therapeutics-logo2.jpg\",\"datePublished\":\"2010-05-05T08:46:09+00:00\",\"dateModified\":\"2015-12-29T12:15:30+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"FDA grants Osiris Orphan Drug Designation for Type 1 Diabetes Stem Cell Treatment. Prochymal, a formulation stem cells (MSC) is being evaluated in Phase II clinical trial. Osiris is developing Prochymal in JDRF as a treatment for type 1 diabetes.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=7367#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=7367\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=7367#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/05\/osiris-therapeutics-logo2.jpg\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/05\/osiris-therapeutics-logo2.jpg\",\"width\":170,\"height\":69,\"caption\":\"osiris-therapeutics-logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=7367#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Stem Cell Treatment for Type 1 Diabetes Receives FDA Orphan Drug Designation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Type 1 Diabetes Stem Cell Treatment Receives FDA Orphan Drug Designation","description":"FDA grants Osiris Orphan Drug Designation for Type 1 Diabetes Stem Cell Treatment. Prochymal, a formulation stem cells (MSC) is being evaluated in Phase II clinical trial. Osiris is developing Prochymal in JDRF as a treatment for type 1 diabetes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=7367","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=7367","url":"https:\/\/asweetlife.org\/?p=7367","name":"Type 1 Diabetes Stem Cell Treatment Receives FDA Orphan Drug Designation","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=7367#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=7367#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/05\/osiris-therapeutics-logo2.jpg","datePublished":"2010-05-05T08:46:09+00:00","dateModified":"2015-12-29T12:15:30+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"FDA grants Osiris Orphan Drug Designation for Type 1 Diabetes Stem Cell Treatment. Prochymal, a formulation stem cells (MSC) is being evaluated in Phase II clinical trial. Osiris is developing Prochymal in JDRF as a treatment for type 1 diabetes.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=7367#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=7367"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=7367#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/05\/osiris-therapeutics-logo2.jpg","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/05\/osiris-therapeutics-logo2.jpg","width":170,"height":69,"caption":"osiris-therapeutics-logo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=7367#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Stem Cell Treatment for Type 1 Diabetes Receives FDA Orphan Drug Designation"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/7367"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7367"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/7367\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/7375"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}